Bonti Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 10

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $285M

Bonti General Information

Description

Developer of a neurotoxin designed for therapeutic and aesthetic indications for patients with unmet needs. The company develops botulinum neurotoxin for the treatment of muscle hyperactivity, the root cause of musculoskeletal pain in both post-surgical and non-surgical settings, enabling patients to have a long-acting, non-opioid local muscle relaxant without the side effects of currently marketed products.

Contact Information

Website
www.bonti.com
Formerly Known As
Endurance Biotech, Endurance Biotech, Inc.
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 4921 Birch Street
  • Suite 120
  • Newport Beach, CA 92660
  • United States
+1 (949)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Allergan
Vertical(s)
Life Sciences
Corporate Office
  • 4921 Birch Street
  • Suite 120
  • Newport Beach, CA 92660
  • United States
+1 (949)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Bonti Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 24-Oct-2018 $285M Completed Clinical Trials - Phase 2
4. Later Stage VC (Series C) 23-Jan-2018 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series B) 10-Apr-2017 Completed Clinical Trials - Phase 2
2. Debt - General 01-Dec-2015 $2M $10.9M Completed Startup
1. Early Stage VC (Series A) 28-Aug-2015 $8.9M $8.9M Completed Startup
To view Bonti’s complete valuation and funding history, request access »

Bonti Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series C
Series B
Series A 7,451,478 $0.000100 8% $1.2 $1.2 1x $1.2 21.14%
To view Bonti’s complete cap table history, request access »

Bonti Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a neurotoxin designed for therapeutic and aesthetic indications for patients with unmet needs. The company
Drug Discovery
Newport Beach, CA
10 As of 2018

Suresnes, France
 

Rockville, MD
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Bonti Competitors (41)

One of Bonti’s 41 competitors is AlgoTx, a Venture Capital-Backed company based in Suresnes, France.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
AlgoTx Venture Capital-Backed Suresnes, France
Regenerx Formerly VC-backed Rockville, MD
viDA Therapeutics Venture Capital-Backed Vancouver, Canada
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Allorion Therapeutics Venture Capital-Backed Natick, MA
You’re viewing 5 of 41 competitors. Get the full list »

Bonti Patents

  • 64

    Total Documents Applications and Grants

  • Total Patents Families

  • 4

    Granted

  • 13

    Pending

  • Expiring in next 12 mo

Bonti Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2019247751-A1 Neurotoxins for use in inhibiting cgrp Inactive 03-Apr-2018
CA-3096032-A1 Neurotoxins for use in inhibiting cgrp Pending 03-Apr-2018
EP-3773906-A1 Neurotoxins for use in inhibiting cgrp Inactive 03-Apr-2018
US-20190300583-A1 Neurotoxins for use in inhibiting cgrp Inactive 03-Apr-2018
US-20220306704-A1 Neurotoxins for use in inhibiting cgrp Inactive 03-Apr-2018 C07K14/33
To view Bonti’s complete patent history, request access »

Bonti Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Bonti Former Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
Biovision Ventures Venture Capital Minority
City Hill Ventures Venture Capital Minority
Colt Ventures Family Office Minority
Highlight Capital Venture Capital Minority
Hunt Technology Ventures Venture Capital Minority
You’re viewing 5 of 10 investors. Get the full list »

Ready to get started?

Request a free trial

Bonti FAQs

  • When was Bonti founded?

    Bonti was founded in 2015.

  • Where is Bonti headquartered?

    Bonti is headquartered in Newport Beach, CA.

  • What is the size of Bonti?

    Bonti has 10 total employees.

  • What industry is Bonti in?

    Bonti’s primary industry is Drug Discovery.

  • Is Bonti a private or public company?

    Bonti is a Private company.

  • What is the current valuation of Bonti?

    The current valuation of Bonti is .

  • What is Bonti’s current revenue?

    The current revenue for Bonti is .

  • How much funding has Bonti raised over time?

    Bonti has raised $38.1M.

  • Who are Bonti’s investors?

    Biovision Ventures, City Hill Ventures, Colt Ventures, Highlight Capital, and Hunt Technology Ventures are 5 of 10 investors who have invested in Bonti.

  • Who are Bonti’s competitors?

    AlgoTx, Regenerx, viDA Therapeutics, Inovio Pharmaceuticals, and Allorion Therapeutics are some of the 41 competitors of Bonti.

  • When was Bonti acquired?

    Bonti was acquired on 24-Oct-2018.

  • Who acquired Bonti?

    Bonti was acquired by Allergan.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process